Key clinical point: Androgen‑deprivation therapy (ADT) is associated with a reduction in the risk of cardiovascular disease (CVD), cardiovascular intervention (CVI), and cerebrovascular disease (CrVD) in men with newly diagnosed prostate cancer.

Major finding: ADT independently decreased the risk of CVD (hazard ratio [HR], 0.890; P less than .0001), CVI (HR, 0.873; P = .0352), and CrVD (HR, 0.869; P less than .0001). The risk of CVD was significantly reduced in patients using ADT for over 2 years. CVI and CrVD risks were significantly lower in those using ADT for over 3 years.

Study details: This population-based study included 131,189 patients with newly diagnosed prostate cancer using the insurance claims data in South Korea. After propensity score matching, the number of patients in the ADT and non-ADT groups was 30,861 each.

Disclosures: The study was supported by Korean Urological Oncology Society research grant. The authors declared no conflicts of interest.